Refine by
Microbiomics Articles & Analysis
186 news found
"LAA breaks through traditional sequencing constraints, empowering researchers with invaluable insights into the most intricate areas of the genome, accelerating their research and making significant contributions to diverse fields, including cancer research, microbiome studies, and precision medicine." CD Genomics' LAA service is fortified by a team of expert scientists and ...
The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role that microbial communities play in maintaining human health. ...
Herb Lin, a managing partner at TPTF, first learned of Bened through his fund’s investment in Finch Therapeutics, a microbiome therapy company now listed on the NASDAQ. He found Bened an attractive investment and noted that its unique R&D capability, including its clinical studies and patent portfolio, placed the company at the forefront of the psychobiotic sector. This ...
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. ...
Sirenas’ insights reveal both extracts and single compounds that modulate inflammation, pathways in cancer, infectious disease and microbiome dynamics. The team at Sirenas is using these findings to help design the next generation of health products, in collaboration with Hume, to bring the untapped and limitless healing power of the ocean to all people. ...
BySirenas
On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be granted orphan drug designation in the field of microbiome-based treatment for metabolic diseases. ...
The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images, and providing digital drug discovery services. ...
ByArdigen
We are investing in the next phase of microbiome health: post-discovery development and commercialization that will efficiently bring products to ...
Addressing the ‘One Health’ opportunity requires a focus on, and a deep understanding of, microbiome3 and host-microbiome interactions as the common denominator across these domains. ...
The company accelerates therapy development by designing immunity, decoding microbiomes, analysing biomedical images and providing digital drug discovery services. ...
ByArdigen
The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images and providing digital drug discovery services. ...
ByArdigen
In the role, Tarun will continue to drive excellence in Eagle Genomics’ technology to deliver the capabilities of its AI-augmented knowledge discovery platform, e[datascientist]™, at scale. e[datascientist]™ uses network science to understand the microbiome in such complex ecosystems that exist within soils, plants, animals and humans, including how they ...
This involves helping to drive innovation and the growth of the bioeconomy by enabling the networking of microbiome science. In 2019, Eagle Genomics graduated from the Microsoft Scale-Up programme (see video here), and achieved full co-sell and One Commercial Partner (OCP) status in a business partnership with Microsoft Azure. In 2018 it announced a partnership with Microsoft ...
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. ...
KINS is a health technology company that supports the care of microbiome, which is responsible for health and vitality throughout the body, and accelerates research while building and analyzing databases of microbiome samples from skin, scalp, intestines, and more. The company recently expanded its business to include the microbiome of dogs and ...
About SER-109 SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome. SER-109 is designed to prevent the recurrence of CDI by restructuring the microbiome to a state that resistsC. difficile colonization and growth. ...
The guidelines’ promotion of IBT’s business strategy, long-term interests and sustainability IBT develops, and intends to market and sell, safe and efficacious therapies that affect infants’ microbiome and thereby prevent or treat rare diseases that affects premature infants. ...
Infant Bacterial Therapeutics AB (publ) (IBT) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...